Cargando…

Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells

Glioblastoma (GBM) is a poorly treatable disease due to the fast development of tumor recurrences and high resistance to chemo- and radiotherapy. To overcome the highly adaptive behavior of GBMs, especially multimodal therapeutic approaches also including natural adjuvants have been investigated. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hellmold, Dana, Kubelt, Carolin, Daunke, Tina, Beckinger, Silje, Janssen, Ottmar, Hauck, Margarethe, Schütt, Fabian, Adelung, Rainer, Lucius, Ralph, Haag, Jochen, Sebens, Susanne, Synowitz, Michael, Held-Feindt, Janka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218802/
https://www.ncbi.nlm.nih.gov/pubmed/37240419
http://dx.doi.org/10.3390/ijms24109075
_version_ 1785048860255584256
author Hellmold, Dana
Kubelt, Carolin
Daunke, Tina
Beckinger, Silje
Janssen, Ottmar
Hauck, Margarethe
Schütt, Fabian
Adelung, Rainer
Lucius, Ralph
Haag, Jochen
Sebens, Susanne
Synowitz, Michael
Held-Feindt, Janka
author_facet Hellmold, Dana
Kubelt, Carolin
Daunke, Tina
Beckinger, Silje
Janssen, Ottmar
Hauck, Margarethe
Schütt, Fabian
Adelung, Rainer
Lucius, Ralph
Haag, Jochen
Sebens, Susanne
Synowitz, Michael
Held-Feindt, Janka
author_sort Hellmold, Dana
collection PubMed
description Glioblastoma (GBM) is a poorly treatable disease due to the fast development of tumor recurrences and high resistance to chemo- and radiotherapy. To overcome the highly adaptive behavior of GBMs, especially multimodal therapeutic approaches also including natural adjuvants have been investigated. However, despite increased efficiency, some GBM cells are still able to survive these advanced treatment regimens. Given this, the present study evaluates representative chemoresistance mechanisms of surviving human GBM primary cells in a complex in vitro co-culture model upon sequential application of temozolomide (TMZ) combined with AT101, the R(-) enantiomer of the naturally occurring cottonseed-derived gossypol. Treatment with TMZ+AT101/AT101, although highly efficient, yielded a predominance of phosphatidylserine-positive GBM cells over time. Analysis of the intracellular effects revealed phosphorylation of AKT, mTOR, and GSK3ß, resulting in the induction of various pro-tumorigenic genes in surviving GBM cells. A Torin2-mediated mTOR inhibition combined with TMZ+AT101/AT101 partly counteracted the observed TMZ+AT101/AT101-associated effects. Interestingly, treatment with TMZ+AT101/AT101 concomitantly changed the amount and composition of extracellular vesicles released from surviving GBM cells. Taken together, our analyses revealed that even when chemotherapeutic agents with different effector mechanisms are combined, a variety of chemoresistance mechanisms of surviving GBM cells must be taken into account.
format Online
Article
Text
id pubmed-10218802
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102188022023-05-27 Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells Hellmold, Dana Kubelt, Carolin Daunke, Tina Beckinger, Silje Janssen, Ottmar Hauck, Margarethe Schütt, Fabian Adelung, Rainer Lucius, Ralph Haag, Jochen Sebens, Susanne Synowitz, Michael Held-Feindt, Janka Int J Mol Sci Article Glioblastoma (GBM) is a poorly treatable disease due to the fast development of tumor recurrences and high resistance to chemo- and radiotherapy. To overcome the highly adaptive behavior of GBMs, especially multimodal therapeutic approaches also including natural adjuvants have been investigated. However, despite increased efficiency, some GBM cells are still able to survive these advanced treatment regimens. Given this, the present study evaluates representative chemoresistance mechanisms of surviving human GBM primary cells in a complex in vitro co-culture model upon sequential application of temozolomide (TMZ) combined with AT101, the R(-) enantiomer of the naturally occurring cottonseed-derived gossypol. Treatment with TMZ+AT101/AT101, although highly efficient, yielded a predominance of phosphatidylserine-positive GBM cells over time. Analysis of the intracellular effects revealed phosphorylation of AKT, mTOR, and GSK3ß, resulting in the induction of various pro-tumorigenic genes in surviving GBM cells. A Torin2-mediated mTOR inhibition combined with TMZ+AT101/AT101 partly counteracted the observed TMZ+AT101/AT101-associated effects. Interestingly, treatment with TMZ+AT101/AT101 concomitantly changed the amount and composition of extracellular vesicles released from surviving GBM cells. Taken together, our analyses revealed that even when chemotherapeutic agents with different effector mechanisms are combined, a variety of chemoresistance mechanisms of surviving GBM cells must be taken into account. MDPI 2023-05-22 /pmc/articles/PMC10218802/ /pubmed/37240419 http://dx.doi.org/10.3390/ijms24109075 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hellmold, Dana
Kubelt, Carolin
Daunke, Tina
Beckinger, Silje
Janssen, Ottmar
Hauck, Margarethe
Schütt, Fabian
Adelung, Rainer
Lucius, Ralph
Haag, Jochen
Sebens, Susanne
Synowitz, Michael
Held-Feindt, Janka
Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells
title Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells
title_full Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells
title_fullStr Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells
title_full_unstemmed Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells
title_short Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells
title_sort sequential treatment with temozolomide plus naturally derived at101 as an alternative therapeutic strategy: insights into chemoresistance mechanisms of surviving glioblastoma cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218802/
https://www.ncbi.nlm.nih.gov/pubmed/37240419
http://dx.doi.org/10.3390/ijms24109075
work_keys_str_mv AT hellmolddana sequentialtreatmentwithtemozolomideplusnaturallyderivedat101asanalternativetherapeuticstrategyinsightsintochemoresistancemechanismsofsurvivingglioblastomacells
AT kubeltcarolin sequentialtreatmentwithtemozolomideplusnaturallyderivedat101asanalternativetherapeuticstrategyinsightsintochemoresistancemechanismsofsurvivingglioblastomacells
AT daunketina sequentialtreatmentwithtemozolomideplusnaturallyderivedat101asanalternativetherapeuticstrategyinsightsintochemoresistancemechanismsofsurvivingglioblastomacells
AT beckingersilje sequentialtreatmentwithtemozolomideplusnaturallyderivedat101asanalternativetherapeuticstrategyinsightsintochemoresistancemechanismsofsurvivingglioblastomacells
AT janssenottmar sequentialtreatmentwithtemozolomideplusnaturallyderivedat101asanalternativetherapeuticstrategyinsightsintochemoresistancemechanismsofsurvivingglioblastomacells
AT hauckmargarethe sequentialtreatmentwithtemozolomideplusnaturallyderivedat101asanalternativetherapeuticstrategyinsightsintochemoresistancemechanismsofsurvivingglioblastomacells
AT schuttfabian sequentialtreatmentwithtemozolomideplusnaturallyderivedat101asanalternativetherapeuticstrategyinsightsintochemoresistancemechanismsofsurvivingglioblastomacells
AT adelungrainer sequentialtreatmentwithtemozolomideplusnaturallyderivedat101asanalternativetherapeuticstrategyinsightsintochemoresistancemechanismsofsurvivingglioblastomacells
AT luciusralph sequentialtreatmentwithtemozolomideplusnaturallyderivedat101asanalternativetherapeuticstrategyinsightsintochemoresistancemechanismsofsurvivingglioblastomacells
AT haagjochen sequentialtreatmentwithtemozolomideplusnaturallyderivedat101asanalternativetherapeuticstrategyinsightsintochemoresistancemechanismsofsurvivingglioblastomacells
AT sebenssusanne sequentialtreatmentwithtemozolomideplusnaturallyderivedat101asanalternativetherapeuticstrategyinsightsintochemoresistancemechanismsofsurvivingglioblastomacells
AT synowitzmichael sequentialtreatmentwithtemozolomideplusnaturallyderivedat101asanalternativetherapeuticstrategyinsightsintochemoresistancemechanismsofsurvivingglioblastomacells
AT heldfeindtjanka sequentialtreatmentwithtemozolomideplusnaturallyderivedat101asanalternativetherapeuticstrategyinsightsintochemoresistancemechanismsofsurvivingglioblastomacells